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Abstract 
 
Some Vinca alkaloids (e.g. vinblastine, vincristine) have been widely used as antitumor drugs 
for a long time. Unfortunately, vindoline, a main alkaloid component of Catharanthus roseus 
(L.) G. Don, itself, has no antitumor activity. In our novel research program we have prepared 
and identified new vindoline derivatives with moderate cytostatic activity. 
Here we describe the effect of conjugation of vindoline derivative with oligoarginine (tetra-, 
hexa- or octapeptides) cell-penetrating peptides on the cytostatic activity in vitro and in vivo. 
Br-Vindoline-(L)-Trp-OH attached to the N-terminus of octaarginine was the most effective 
compound in vitro on HL-60 cell line. Analysis of the in vitro activity  of two isomer 
conjugates (Br-vindoline-(L)-Trp-Arg8 and Br-vindoline-(D)-Trp-Arg8 suggest the covalent 
attachment of the vindoline derivatives to octaarginine increased the antitumor activity 
significantly against P388 and C26 tumour cells in vitro. The cytostatic effect was dependent 
on the presence and configuration of Trp in the conjugate as well as on the cell line studied. 
The configuration of Trp notably influenced of the activity on C26 and P388 cells: conjugate 
with (L)-Trp was more active than conjugate with the (D)-isomer. In contrast conjugates had 
very similar effect on both the HL-60 and MDA-MB-231 cells. In preliminary experiments 
conjugate Br-vindoline-(L)-Trp-Arg8 exhibited some inhibitory effect on the tumor growth in 
P388 mouse leukemia tumor-bearing mice. Our results indicate that the conjugation of 
modified vindoline could result in an effective compound even with in vivo antitumor activity. 
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Introduction 
 
Vinca alkaloids were first isolated from the leaves of Catharanthus roseus (L.) G. Don. The 
major alkaloid in this plant is vindoline
1,2
. Some of the minor alkaloids (e.g. vincristine, 
vinblastine) of this plant have been widely used as antitumor drugs for a long time. These 
bisindole alkaloids, which contain a rearranged catharanthine and vindoline moiety, disturb 
the dynamics of microtubular system causing microtubule instability
3,4
. Vindoline, the most 
complex part of bisindole alkaloids, is considered as their bio- as well as synthetic precursor. 
Unfortunately, early studies showed that vindoline does not exhibit any antitumor activity but 
it might be functioning as the anchor in the binding of bisindole alkaloids to tubulin
5
. Because 
small structural changes may cause drastic differences in the antitumor efficacies, potencies, 
and side effects, much synthetic effort has been directed toward modifying the structure of 
Vinca alkaloids to obtain efficient drug candidates. One of the first such attempts was to 
prepare 17-desacetylvinblastine derivatives by the replacement of the methyl ester group at 
position C-16 in the vindoline part with an amide group (vindesine)
6
 and then to modify this 
group by incorporating different alkyl groups or amino acids
7,8
. Among the amino acid 
derivatives, the presence of hydrophobic amino acid (Leu, Ile, Val, or Trp) exhibited 
pronounced activity. The Trp-OEt derivative was found to be very active on P388 and L1210 
leukemia cells implanted intravenously in DBA/2 mice. For further improvement, by 
modification of the vindoline ring system a new set of compounds was prepared
9
 and attached 
to (L)- or (D)-Trp-OMe
10
. These conjugates showed higher in vitro cytostatic activity on HL-
60 human leukemia cells, while the unmodified vindoline was inefficient even at 100 µM 
concentration. It should be noted that the (L)- and (D)-Trp containing derivatives showed 
lower activity as compared to vinblastine. 
Cell-penetrating peptides (CPP), mainly positively charged short amino acid sequences, are 
able to pass through the cell membrane
11
. Based on the experimental data, the family of cell-
penetrating peptides can be divided into three main classes; (a) primary amphipathic, (b) 
secondary amphipathic and (c) non-amphipathic cell-penetrating peptides
12
. Oligoarginines 
were de novo designed in accord with early-discovered CPPs containing several arginine 
residues in their sequences
13
. Among these compounds octaarginine (Arg8) was found to be a 
CPP with optimal length for efficient internalization into mouse macrophage RAW264.7 
cells
14
. Based on these observations octaarginine was used frequently to transport different 
molecular cargos into cells. We also used successfully this peptide to deliver calpain enzyme 
substrate peptide
15
 and antitumor drug (daunomycin, vinblastine, pemetrexed or 
methotrexate)
16-19
. 
Previously, we prepared and studied the (L)-Trp modified derivatives of 17-
desacetylvinblastine
16
 with essentially the same activity on human leukemia cells (HL-60) as 
that of vinblastine sulfate, a drug used in cancer treatment. Conjugation with octaarginine 
preserved the activity of the free isomers on both sensitive (HL-60) and drug-resistant 
leukemia cells (HL-60-MRP1and HL-60-MDR1). 
The biological data obtained with these Trp derivatives of vinblastine inspired us to prepare 
vindoline derivative isomers and isomer conjugates. Thus, the (L)- and (D)-Trp derivatives of 
Br-vindoline and conjugates with oligoarginines were prepared by solution-phase conjugation 
and the in vitro cytostatic effect was studied on several tumor cell lines. In addition, the in 
vivo antitumor effect of conjugates was analyzed in two mouse tumor models.       
 
 
Materials and Methods 
 
General Procedures  
Analytical RP-HPLC was performed a) on an Exformma (Exformma Technology (ASIA) Co., 
Ltd, Hong Kong, China) HPLC system using an Agilent Zorbax SB-C18 column (4.6mm x 
150mm, I.D., 100Å pore size, 5 µm silica), linear gradient elution (0 min 0% B, 2 min 0% B, 
22 min 90% B) with eluent A (0.1% TFA in water) and eluent B (0.1% TFA in acetonitrile-
water (80:20, V/V)) was used at a flow rate of 1 mL/min at ambient temperature, or  b) a 
Knauer (H. Knauer GmbH, Berlin, Germany) HPLC system using Phenomenex SYNERGY 
MAX-RP (4.6mm x 250mm, I.D., 80 Å pore size, 4 µm silica), linear gradient elution (0 min 
0% B, 5 min 0% B, 50 min 90% B) with eluent A and eluent B was used at a flow rate of 1 
mL/min at ambient temperature. The UV detection was carried in both cases at λ = 220 nm. 
The peptides were purified on a semi-preparative Phenomenex Jupiter C18 column 
(250x10mm I.D. 300 Å pore size, 10 µm silica (Torrance, CA, USA). The flow rate was 4 
mL/min. Linear gradient elution (0 min 0% B; 5 min 0 % B, 50 min 50 % B) and UV 
detection (λ = 220 nm) was applied. The conjugates were purified by using the same system 
and condition, but the linear gradient was 0 min 25% B; 5 min 25 % B, 50 min 70 % B. 
TLC was carried out using Kieselgel 60 F254 (Merck) glass plates. 
The molecular mass of peptides and conjugates was determined by ESI-MS was performed on 
a Bruker Daltonics Esquire 3000 plus (Germany) ion trap mass spectrometer. The samples 
were dissolved in acetonitrile–water (50:50, V/V), containing 0.1% acetic acid. 
Melting points were measured on VEB Analytik Dresden PHMK-77/1328 apparatus and are 
uncorrected. IR spectra were recorded on Zeiss IR 75 and 80 instruments. NMR 
measurements were performed on a Varian 800 MHz NMR spectrometer equipped with a 
1
H{
13
C/
15
N} Triple Resonance 
13
C Enhanced Salt Tolerant Cold Probe operating at 800 MHz 
for 
1
H and 201 MHz for 
13
C, and a Varian 500 MHz NMR spectrometer equipped with a 
1
H 
{
13
C/
15
N} 5 mm PFG Triple Resonance 
13
C Enhanced Cold Probe operating at 500 MHz for 
1
H and 125 MHz for 
13
C. Chemical shifts are given on the delta scale as parts per million 
(ppm) with tetramethylsilane (TMS) (
1
H) or dimethylsulfoxide-d6 (
13
C) as the internal 
standard (0.00 ppm and 39.5 ppm, respectively). 
1
H-
1
H, direct 
1
H-
13
C, and long-range 
1
H-
13
C 
scalar spin-spin connectivities were established from 2D gDQFCOSY, zTOCSY, gHSQCAD, 
and gHMBCAD experiments, respectively. All pulse sequences were applied by using the 
standard spectrometer software package. All experiments were performed at 298 K. HRMS 
analyses were performed on an LTQ FT Ultra (Thermo Fisher Scientific, Bremen, Germany) 
system. The ionization method was ESI operated in positive ion mode. For the CID experiment 
helium was used as the collision gas, and normalized collision energy (expressed in percentage), 
which is a measure of the amplitude of the resonance excitation RF voltage applied to the 
endcaps of the linear ion trap, was used to induce fragmentation. The protonated molecular ion 
peaks were fragmented by CID at a normalized collision energy of 35–55%. The samples were 
dissolved in methanol. Data acquisition and analysis were accomplished with Xcalibur software 
version 2.0 (Thermo Fisher Scientific). 
 
Synthesis of vindoline derivatives 
The synthesis of the methyl esters of Br-vindoline-Trp-OMe and Br-vindoline-D-Trp-OMe 
conjugate was described earlier
10
. The esters were then hydrolysed using LiOH x H2O in 
MeOH. The methyl ester derivatives (1a and 1b) were dissolved in a mixture of MeOH and 
distilled water (3:1 V/V ratio at c= 0.04 M), and lithium hydroxide monohydrate (8 eqv.) was 
added. The reaction mixture was kept in a refrigerator at 4 
o
C for 24 h. 10 mL of distilled 
water was then added to the solution and the methanol was evaporated in vacuum. The 
solution was acidified to pH 7 with 5% HCl and evaporated to dryness in vacuum. The crude 
product was purified by preparative TLC. 
 
N-[10-bromo-17-O-desacetyl-16-des(methoxycarbonyl)vindoline-16-carbonyl]-L-tryptophan 
(2a) 
167 mg (0.246 mmol) methyl ester (1a) was hydrolysed and the crude product was purified by 
preparative TLC (CHCl3-MeOH 7:3, V/V) and 70 mg (29 %) of 2a was isolated as pale 
yellow crystals. Mp 251-253 
o
C (decomp.). TLC (CHCl3-MeOH 7:3), Rf =0.44. 
IR (KBr) 3406, 1655, 1605, 1498, 1458, 1229, 746 cm
-1
. 
1
H NMR (799.7 MHz, DMSO-d6) δ 0.62 (3H, t, J 7.5 Hz, H3-18), 0.88 (1H, dq, J 13.5, 7.5 
Hz, Hy-19), 1.33 (1H, dq, J 13.5, 7.5 Hz, Hx-19), 2.04–2.11 (2H, m, Hx-6 and Hy-6), 2.53–
2.58 (1H, m, Hy-5), 2.69 (4H, s, N(1)-CH3, H-21), 2.80 (1H, br d, J 16.3 Hz ,Hy-3), 3.13–3.18 
(2H, m, Hx-1’’ and Hy-1’’), 3.19–3.23 (1H, m, Hx-5), 3.32–3.36 (1H, buried m, Hx-3), 3.37 
(1H, s, H-2), 3.79 (3H, s, C(11)-OCH3), 3.80–3.90* (2H, overlapping singlet and broad 
resonance, H-17 and C(17)-OH), 4.20–4.32 (1H, m, H-2’’), 5.54 (1H, br d, J 10.2 Hz, H-15), 
5.76 (1H, dd, J 10.2, 5.1 Hz, H-14), 6.24 (1H, s, H-12), 6.90 (1H, dd, J 7.6, 7.4 Hz, H-5’), 
7.00 (1H, dd, J 8.1, 7.4 Hz, H-6’), 7.15 (1H, br, H-2’), 7.23 (1H, s, H-9), 7.27 (1H, d, J 8.1 
Hz, H-7’), 7.58 (1H, d, J 7.6 Hz, H-4’), 7.75 (1H, d, J 7.6 Hz, H-4’’), 8.68* (1H, br, C(16)-
OH), 10.71 (1H, br, H-1’). 13C NMR (201.1 MHz, DMSO-d6) δ 7.5 (C-18), 27.4 (C-1’’), 31.9 
(C-19), 37.9 (N(1)-CH3), 42.1 (C-20), 44.4 (C-6), 50.26 (C-5), 50.35 (C-3), 52.0 (C-7), 53.7* 
(br, C-2’’), 56.0 (C(11)-OCH3), 66.9 (C-21), 72.9 (C-17), 79.3 (C-16), 83.8 (C-2), 93.4 (C-
12), 96.9 (C-10), 110.5* (br, C-3’), 110.8 (C-7’), 117.7 (C-5’), 118.8 (C-4’), 120.3 (C-6’), 
122.6 (C-14), 123.5 (C-2’), 126.0 (C-9), 126.5 (C-8), 127.8 (C-3a’), 131.4 (C-15), 135.7 (C-
7a’), 153.0 (C-13), 155.7 (C-11), 170.9* (br, C-3’’), 170.9 (C(16)-CONH), *: assignment of 
exchanging resonances may be uncertain. 
HRMS: M+H=665.19653 (C33H38O6N4Br; delta=-0.6 ppm). HR-ESI-MS-MS (CID=35 %) 
rel. int. %): 647(100); 619(2); 479(8); 443(23); 433(23); 373(3). 
 
N-[10-bromo-17-O-desacetyl-16-des(methoxycarbonyl)vindoline-16-carbonyl]-D-tryptophan 
(2b) 
249 mg (0.366 mmol) methyl ester (1b) was hydrolysed and the crude product was purified 
by preparative TLC (CHCl3-MeOH 7:3, V/V) and 126 mg (52 %) of 2b was isolated as pale 
yellow crystals. Mp 215-217 
o
C (decomp.). TLC (CHCl3-MeOH 7:3), Rf =0.28. 
IR (KBr) 3406, 1649, 1605, 1499, 1040, 746 cm
-1
. 
1
H NMR (499.9 MHz, DMSO-d6) δ 0.58 (3H, t, J 7.3 Hz, H3-18), 0.82 (1H, dq, J 13.3, 7.3 
Hz, Hy-19), 1.24–1.31 (1H, buried m, Hx-19), 1.95–2.10 (2H, m, Hx-6 and Hy-6), 2.23 (3H, s, 
N(1)-CH3), 2.51–2.58 (1H, m, Hy-5), 2.60 (1H, s, H-21), 2.79 (1H, br d, J 15.6 Hz ,Hy-3), 
3.05–3.13 (2H, overlapping broad resonances, Hy-1’’, H-2), 3.15–3.38 (3H, buried m, Hx-3, 
Hx-5, Hx-1’’), 3.74 (3H, s, C(11)-OCH3), 3.81–4.01* (2H, overlapping singlet and broad 
resonance, H-17 and C(17)-OH), 4.17–4.30 (1H, br, H-2’’), 5.52 (1H, br d, J 10.7 Hz, H-15), 
5.73 (1H, dd, J 10.7, 5.0 Hz, H-14), 6.13 (1H, s, H-12), 6.94 (1H, dd, J 7.6, 7.4 Hz, H-5’), 
7.01 (1H, dd, J 8.1, 7.4 Hz, H-6’), 7.17–7.23 (2H, overlapping singlet and broad resonance, 
H-2’ and H-9), 7.28 (1H, d, J 8.1 Hz, H-7’), 7.57 (1H, d, J 7.6 Hz, H-4’), 8.00 (1H, br d, J 5.0 
Hz, H-4’’), 8.88* (1H, br, C(16)-OH), 10.71 (1H, br, H-1’), 13C NMR (125.7 MHz, DMSO-
d6) δ 7.5 (C-18), 27.7 (C-1’’), 31.9 (C-19), 37.9 (N(1)-CH3), 42.1 (C-20), 44.5 (C-6), 50.2 (C-
3), 50. 5 (C-5), 52.0 (C-7), 54.3* (br, C-2’’), 56.0 (C(11)-OCH3), 67.3 (C-21), 72.8 (C-17), 
79.4 (C-16), 83.6 (C-2), 93.4 (C-12), 97.0 (C-10), 110.9 (C-7’), 111.2 (C-3’), 117.7 (C-5’), 
118.4 (C-4’), 120.4 (C-6’), 122.4 (C-14), 123.2 (C-2’), 125.9 (C-9), 126.6 (C-8), 127.9 (C-
3a’), 131.4 (C-15), 135.8 (C-7a’), 153.0 (C-13), 155.7 (C-11), 171.6* (br, C-3’’), 171.6 
(C(16)-CONH) *: assignment of exchanging resonances may be uncertain. 
HRMS: M+H=665.19645 (C33H38O6N4Br; delta=-0.7 ppm). HR-ESI-MS-MS (CID=35 %) 
rel. int. %): 647(100); 619(3); 479(5); 443(18); 433(19); 373(3). 
 
Synthesis of the conjugates of vindoline derivatives with oligoarginine 
Oligoarginines (tetra-, hexa- and octaarginine) was synthesised on Rink Amide MBHA resin 
using standard Fmoc/
t
Bu strategy as described before
19
. After cleavage from the resin the 
crude product was purified by RP-HPLC and was allowed to react with vindoline derivatives 
as reported earlier
16
. Briefly, the vindoline derivatives (2a and 2b) were conjugated with 
oligoarginine in DMF using 1.2 eqv. HOBt and DIC as the coupling reagents in the presence 
of 5 eqv. DIEA as the base. The conjugation reaction proceeded for 6 h at RT. DMF was then 
evaporated in vacuum, the crude product was dissolved in eluent A and was purified by RP-
HPLC as described above. The Br-vindoline-Arg8 conjugate was prepared by the reaction of 
10-bromo-17-dezacetylvindoline-16-carboxylic acid hydrazide and H-Arg8-NH2 as described 
earlier
10
 with one modification. The octaarginine component was dissolved in DMF instead of 
DCM. The solvents were then evaporated and the residue was dissolved in the mixture of 
eluent A and B (3:1 V/V) and purified by RP-HPLC as described above. 
 
Cell cultures for in vitro studies 
For the analysis of in vitro cytostatic effect MCF-7 (ATCC: HTB-22)
20
, MDA-MB-231 
(ATCC: HTB-26)
21
 and HL-60 (ATCC: CCL-240)
22
 cells were used. MCF-7, human breast 
adenocarcinoma cells were maintained in DMEM supplemented with 10% heat-inactivated 
foetal calf serum (FCS), non-essential amino acids (NEAA), pyruvate (1 mM), L-glutamine (2 
mM) and gentamicin (160 µg/ml). HL-60 human promyelocytic leukemia cells were grown in 
RPMI-1640 supplemented with 10% FCS, (L)-glutamine (2 mM) and gentamicin (160 
µg/ml). MDA-MB-231 human triple negative breast adenocarcinoma cells were cultured in 
RPMI-1640 supplemented with 10% FCS, (L)-glutamine (2 mM) and gentamicin (16 µg/ml). 
Cells were maintained in plastic tissue culture dishes at 37°C with a humidified atmosphere 
containing 5% CO2 / 95% air. 
P388 mouse leukemia and C26 murine colon carcinoma cell lines were obtained from ATCC. 
Cells were grown in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO) containing 
penicillin-streptomycin (Sigma) and supplemented with 10% heat-inactivated fetal bovine 
serum (FBS, Sigma) at 37°C in a humidified atmosphere with 5% CO2. 
 
Analysis of the in vitro cytostatic activity of the conjugates 
The in vitro cytostatic effect of the compounds was evaluated by the 3-(4,5-dimethylthiazol-2-
yl)-2,5- diphenyltetrazolium bromide-assay (MTT-assay) on HL-60, MDA-MB-231,
 
MCF-7 
C26 and P388 cells. The cells were grown to confluency in a cell culture flask and were then 
plated into a 96-well plate with an initial cell number of 5.0x10
3
, and in the case of P388, a 
2.0x10
4
 per well. After 24 h of incubation at 37°C, cells were treated with the compounds at a 
1.28x10
-3
-100 µM concentration range for 3 h in a 200 μL final volume. Control cells were 
treated with serum-free medium only at 37°C for 3 h. After incubation the cells were washed 
twice with serum-free medium and further cultured up to 72 h in serum-containing medium. 
In order to evaluate cell viability, an MTT assay
23,24
 was carried out and the IC50 value was 
determined. Briefly, 45 μL of MTT solution (2 mg/mL, in serum-free medium) was added to 
each well following 4 h of incubation, plates were centrifuged at 900 g for 5 min, and the 
supernatant was removed. The precipitated purple crystals were dissolved in 100 μL of 
DMSO and the absorbance was determined at λ = 540 nm and λ = 620 nm using ELISA plate 
reader (iEMS Reader, Labsystems, Finland). The percentage of cytostasis was calculated 
using the following equation: Cytostatic effect (%) = [1 – (ODtreated/ODcontrol)] x100; where 
ODtreated and ODcontrol correspond to the optical densities of the treated and untreated cells, 
respectively. In each case three independent experiments were carried out with 4 parallel 
measurements. The 50% inhibitory concentration (IC50) values were determined from the 
dose-response curves. The curves were defined by using MicrocalTM Origin1 (version 9.2) 
software: cytostasis was plotted as a function of concentration, fitted to a sigmoidal curve, and 
the IC50 value was determined. IC50 represents the concentration of a compound that is 
required for 50% inhibition of in vitro proliferation and expressed as micromolar units. 
 
Experimental Animals 
First generation of hybrid BDF1 (C57BL/6 female and DBA/2 male) adult female mice, and 
BALB/c female mice, weighing 22-24 g from our specified pathogen-free (SPF) animal 
colonies (Department of Experimental Pharmacology, National Institute of Oncology, 
Budapest, Hungary) were used. The animals were kept in makrolon cages at 22-24°C (40-
50% humidity), with a lighting regimen of 12/12 h light and dark. The animals had free access 
to tap water and were fed with a sterilized standard diet (Charles River VRF1, autoclavable, 
Germany) ad libitum. The animals used in these studies were cared for according to the 
„Guiding Principles for the Care and Use of Animals” based upon the Helsinki declaration 
and they were approved by the local ethical committee (permission number: PEI/001/2574-
6/2015). 
 
Analysis of the in vivo antitumor activity of the conjugates  
The antitumor activity of the conjugates was studied on P388 (mouse leukemia) and C26 cells 
(murine colon carcinoma) in BDF1 or BALB/c mice. 
Solid tumor models: P388 and C26 cells (1-2 x 10
6
 in 200 µl serum-free medium per mouse) 
were injected subcutaneously into BDF1 or BALB/c mice (females, 7-10 animals per group), 
respectively. The animals were treated at Day1 and Day6 after tumor cell inoculation with the 
tested compounds at doses of 10, 20, and 40 mg/kg. Two dimensions (length and width) of 
the growing tumor were measured by caliper three times per week and tumor volumes were 
calculated using the formula: length x width
2
 x π/6. The treatments were terminated between 
Day22-33, respectively.  
 
Results 
 
Vinca alkaloids are clinically used drugs against several kinds of tumors. Unfortunately, only 
the minor alkaloid components of Catharanthus roseus (L.) G. Don were found to be 
effective. The major alkaloid of the plant– vindoline – exhibited no antitumor activity25. In 
our ongoing project with Vinca alkaloids effective vinblastine conjugates with octaarginine
16
 
and various vindoline derivatives with modest activity
10
 were synthesized. We described 
earlier that derivatives of Br-vindoline containing (L)- or (D)-Trp-OMe moiety could exhibit  
moderate cytostatic activity
10
. Here we report on studies in which the effect of conjugation 
with cell-penetrating peptides on this activity was investigated. 
 
Synthesis of Br-vindoline derivatives with/without (L)- or (D)-Trp-OMe 
Vindolines substituted at position 10 (1a, b) were coupled with amino acid esters as described 
before
10
. The esters (1a, b) were treated in a methanol-water mixture with lithium hydroxide 
(Scheme 1) at 4 °C to produce compounds with free carboxylic acid function for peptide 
conjugation (2a, b). The synthesis of 10-bromo-17-dezacetylvindoline-16-carboxylic acid 
hydrazide (3) was presented by us earlier
10
. 
 
Synthesis of vindoline derivative-oligoarginine conjugates 
Oligoarginines are well-known cell-penetrating peptides which can deliver a wide range of 
compounds into cells efficiently. Our earlier results indicated also that octaarginine was the 
most effective compound in the delivery of antitumor drugs (e.g. vinblastine, daunomycin) 
into cell
16,17
. This activity was dependent on the number of Arg residues present in the 
conjugate. Therefore here we have also studied the effect of the chain length of oligoarginine 
on the activity of vindoline conjugates and conjugates of Br-vindoline-(L)-Trp-OH (Scheme 2 
a) with tetra-, hexa- or octaarginine were synthesized. Earlier in the case of the vinblastine-
Trp-OH conjugates
16
 we observed that the configuration of Trp had high impact on the 
biological activity, the octaarginine conjugates of Br-vindoline with (L)- and (D)-Trp-OH 
were prepared and comparatively studied. In order to evaluate the importance of the Trp 
moiety, the 10-bromo-17-dezacetylvindoline-16-carboxylic acid hydrazide was also directly 
coupled to the most effective oligoarginine (octaarginine, Scheme 2 b).  
The oligoarginines (tetra-, hexa- and octaarginines) were built up by Fmoc/
t
Bu strategy with a 
free N-terminal amino group and carboxamid C-terminus. The purified peptides were then 
conjugated with the vindoline derivatives in solution by the in situ active ester strategy in 
DMF using DIC and HOBt as the coupling reagents. The conjugates were purified by RP-
HPLC and analyzed by analytical RP-HPLC and ESI-MS mass spectrometry (Table 1). The 
conjugation of Br-vindoline and octaarginine was carried out as described earlier
10
 with some 
modification.  
 
In vitro cytostatic effect of conjugates 
First, we studied the effect of the length of oligoarginine on antitumor activity by comparing 
in vitro cytotoxicity of tetra-, hexa- and octaarginine conjugates on HL-60 cells (Table 2). 
While oligoarginine and Br-vindoline had no effect, the Trp derivative of Br-vindoline (2a) 
exhibited some moderate activity [IC50 = 83.1 ± 10.7 µM]. This could be increased by 
conjugation with oligoarginine. The presence of tetraarginine already enhanced the biological 
activity of (2a), but the presence of eight arginine residue had the most pronounced influence 
[IC50 = 12.9 ± 4.4 µM].  
In the next set of experiments the analysis of in vitro cytostatic effect of compounds and 
octaarginine conjugates was extended to  various tumor cell lines – HL-60, MCF-7, MDA-
MB-231, C26 and P388 (Table 3). Considering our previous observation on the marked effect 
of the configuration on activity with vinblastine-Trp-OH isomer conjugates (with L- or D-Trp 
enantiomer)
16
, the analysis of the D-Trp containing compounds were also incorporated (Table 
3).    
As expected vindoline and Br-vindoline expressed no activity on any cell lines studied (HL-
60, MDA-MB-231, MCF-7, C26 and P388 cell lines). The presence of Trp-OMe moiety 
almost regardless to the configuration of the Trp residue, increased the antitumor effect of Br-
vindoline and the studied derivatives (1a, b) had moderate biological activity in a range of 
IC50 = 73.8 ± 10.4 M - 5.3 ± 1.5 M. It is interesting to note that in case of P388 cells, 
compounds 1a and 1b had not only the most marked effect, but also slightly different activity 
depending on the Trp configuration (IC50 = 5.3 ± 1.5 M for L-Trp, and IC50 = 15.9 ± 2.8 M 
for D-Trp, respectively).  
The corresponding IC50 values derived from the treatment of cells with octaarginine 
conjugates indicated the same tendency: the (L)-Trp containing conjugate (Br-Vind-(L)-Trp-
Arg8) was more effective (IC50 = 3.1 ± 0.5 M) as compared with the isomer conjugate (Br-
Vind-(D)-Trp-Arg8) (IC50 = 18.0 ± 1.2 M).  
The conjugates with Br-vindoline-(L)-Trp-OH or Br-vindoline-(D)-Trp-OH had cytostatic 
activity on other cell lines as well and this effect was generally higher or essentially the same 
(e.g. P388) in comparison with the free, unconjugated vindoline derivatives (1a, b). It is 
important to mention that conjugates of Br-vindoline without the Trp moiety (Br-Vind-Arg8) 
were slightly less effective on MCF7, C26 and P388 cells. The in vitro cytostatic activity was 
also dependent on the cell line: very similar effect of octaarginine conjugates was observed on 
HL-60 and MDA-MB-231 cells with IC50 values in the range of IC50 = 11.5-15.1 μM and IC50 
= 10.0-15.1 μM, respectively.  On the other hand, the configuration of Trp notably determined 
the influence of the conjugate on the activity on C26 and P388 cells: conjugate with (L)-Trp 
was more active than conjugate with the (D)-isomer.  
 
In vivo antitumor activity of conjugates 
The effect of Trp containing conjugates on the tumor growth was studied in vivo by using two 
tumor models. P388 (mouse leukemia) and C26 cells (murine colon carcinoma) were injected 
subcutaneously into mice. Then the animals were treated with the conjugate on Day 1 and 6 at 
10 mg/kg body weight concentrations. Vinblastine as a clinically used drug was used as 
positive control (1 mg/kg body weight). In the case of P388 tumor we observed differences:  
the treatment with conjugate containing (L)-tryptophan [Br-vind-(L)-Trp-Arg8] conjugate 
exhibited a tendency to inhibit the tumor growth (Figure 1), while conjugates with (D)-
tryptophan (Br-vind-(D)-Trp-Arg8) had essentially no inhibitory effect.. It is interesting to 
mention that the Br-vind-(L)-Trp-Arg8 conjugate – under these conditions –was slightly, but 
not significantly more influential that vinblastine, a known cytostatic agent. 
In contrast, the treatment of  C26 colon carcinoma with isomer conjugates (Br-vind-(L)-Trp-
Arg8 or Br-vind-(D)-Trp-Arg8 conjugate) essentially no change in the tumor volume was 
observed. Interestingly the vinblastine treatment had no marked influence on tumor growth 
(Figure 2).  
Discussion 
Vinca alkaloids – vinblastine, vincristine – are effective and clinically used antitumor drugs. 
Unfortunately, one of the major alkaloids – vindoline – has not antitumor activity7,8. In our 
research program some vindoline derivatives were synthesized and their in vitro cytostatic 
activity was characterized
10
. While vindoline has no antitumor activity
25
, some of its 
derivatives (e.g. Br-vindoline-(L/D)-Trp-OMe) could have same modest activity. 
Thus these compounds might provide new avenues for tumor treatment with a new group of 
vinca alkaloid derivatives. The mechanism of action of this novel vindoline derivatives could 
be different from the clinically used compounds (vinblastine, vincristine) and could result in 
more efficient treatment.  
We observed earlier that conjugation of vinblastine to octaarginine retained the activity and 
the conjugates showed selectivity for inhibiting the mitotic spindle formation. Thus Br-
vindoline-(L/D)-Trp-OMe derivatives were selected for studying the effect of conjugation 
with oligoarginine as a cell-penetrating peptide
16
. For analyzing the effect of tryptophan on 
the biological activity 10-Br-vindoline (3), 10-Br-vindoline-(L)-Trp-OH (1a) and 10-Br-
vindoline-(D)-Trp-OH (1b) were conjugated with oligoarginine with different length. The 
effect of the chirality of tryptophan on the biological activity was investigated. For 
conjugation Br-vindoline derivatives were coupled to the N-terminal amino group of 
oligoarginine in solution (Scheme 2).  
Considering that vinca alkaloids are typically used in the treatment of cancerous diseases of 
the blood (non-Hodgkin’s lymphoma, Hodgkin's disease)26 the effect of conjugation was 
studied on HL-60 cells. The conjugation with tetra-, hexa- and octaarginine increased 
drastically the cytostatic effect in comparison to the effect of methyl esters (1a, 1b) or a 
carboxylic acid derivative (2a). Although all conjugates had a cytostatic effect, the conjugate 
with octaarginine showed the highest activity which is in good correlation with earlier data. In 
further experiments only the effect of conjugates with octaarginine was investigated. 
In the next step the antitumor effect of octaarginine conjugates of Br-vindoline derivatives 
with/without Trp residue was studied in vitro on several cell lines. The compounds expressed 
an antitumor effect in vitro on human leukemia (HL-60) and breast cancer (MDA-MB-231 
and MCF-7) cells too. Although the Trp-OMe residue increased the efficacy of Br-vindoline, 
it had no influence in the conjugates on HL-60 and MDA-MB-231 cells, all conjugates had 
essentially the same activity. In contrast, conjugates with Trp were more active on the MCF-7 
cells, but the cytostatic activity was independent of the configuration of tryptophan moiety. 
The effect was also studied on mouse leukemia (P388) and murine colon carcinoma cells 
(C26). On these cells all conjugates have cytostatic effect, but the Trp increased this activity, 
and its configuration also has influence on the activity. Conjugate with (L)-tryptophan was 
twice or six times active on P388 and C26 cells, respectively. These data showed that the 
conjugation with octaarginine, the well-known cell-penetrating peptide, increased the activity 
of the moderately active vindoline derivatives. Both the presence of Trp
27
 and octaarginine 
could increase the cellular-uptake and thus the activity of Br-vindoline derivatives.  
Based on the in vitro results the Br-vind-(L)-Trp-Arg8 and Br-vind-(D)-Trp-Arg8 conjugates 
were selected for preliminary in vivo study using mouse tumor models. We observed that the 
configuration of Trp had some impact on the activity; the conjugate with (L)-isomer was more 
active than with (D)-isomer. Although both conjugates were active in vitro on these cells, in 
the case of mouse P388 leukemia  cells, only the Br-vind-(L)-Trp-Arg8 conjugate could 
inhibit the tumor growth at 10 mg/kg concentration. Since no effect was documented on C26 
murine colon carcinoma cells, one can conclude that the isomer-related effect is also 
dependent on the properties of the tumor investigated. For further studies are planned to 
optimize the conditions and also inclusion of other tumor models are considered. 
This study demonstrated that vindoline, the main alkaloid component of Catharanthus roseus 
(L.) G. Don., has a potency to be chemically transformed to an active anticancer agent. To the 
best of our knowledge, the conjugates reported here are the first vindoline derivatives with 
significant in vitro antitumor activity. Conjugates reported in this paper were effective against 
certain types of tumor cells in vitro at micromolar range. Our results indicate that conjugation 
with oligoarginine as cell-penetrating peptide could increases the in vitro antitumor effect of 
the free vindoline derivative. Preliminary in vivo results presented might also indicate the 
antitumor potency of conjugate. It is important to emphasize that the role of cell-penetrating 
peptide in this effect needs to be clarified. It is worth mentioning that the octaarginine part of 
conjugates might increase the tumor accumulation of conjugates.
28
 It is attractive to speculate 
that the vidoline based derivatives/conjugates could be considered as a potential new member 
of the vinca alkaloid family (e.g. vincristine, vinblastine) with different tumor cell targeting 
mechanism.  
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Table 1 Chemical characteristics of conjugates 
 
Compounds 
Rt (min) ESI-MS
c
 
 Mcal. Mmeas. 
Br-Vind-Arg8* 10.2
a
 1727.9 1728.6 
Br-Vind-(L)-Trp-Arg4 28.7
b
 1289.3 1289.0 
Br-Vind-(L)-Trp-Arg6 27,9
b
 1601.7 1601.4 
Br-Vind-(L)-Trp-Arg8 13.5
a
 or 27.2
b
 1914.1 1914.9 
Br-Vind-(D)-Trp-Arg8 13.5
a
 1914.1 1914.9 
* Argn: H-(Arg)n-NH2 
a 
Column: Agilent Zorbax SB-C18 4.6x150mm, 100Å; Gradient: 0 min 0% B, 2 min 0% B, 22 min 90% B; 
Flow rate:1mL/min; RT, λ=220 nm. 
b
 Column: Agilent Zorbax SB-C18 4.6x150mm, 100Å; Gradient: 0 min 0% B, 2 min 0% B, 22 min 90% B; 
Flow rate:1mL/min; RT, λ=220 nm. 
c 
ESI-MS analysis was carried out on a Bruker Esquire 3000 plus equipment (Germany). The sample was 
dissolved in acetonitrile-water (50:50, V/V), 0.1% acetic acid.  
Table 2 In vitro cytostatic activity of vindoline-derivative and -conjugates on sensitive 
HL-60 tumour cells: the effect of the length of oligoarginine 
Compound 
IC50 (sd) (µM) 
HL-60 
Arg8 > 800 
Br-Vindoline > 100 
Br-Vind-(L)-Trp-OH (2a) 83.1 (10.7) 
Br-Vind-(L)-Trp-Arg4 29.9 (18.1) 
Br-Vind-(L)-Trp-Arg6 21.4 (1.1) 
Br-Vind-(L)-Trp-Arg8 12.9 (4.4) 
a The cells were incubated with the compound for 3 h, after cultured in serum-containing medium 
for 3 days. The IC50 values were determined by MTT assay as described in the text. Standard 
deviation values (sd) are also presented. 
  
Table 3 In vitro cytostatic activity of vindoline-derivatives and -conjugates on tumor cell 
lines 
Compound 
IC50 (sd) (µM) 
HL-60 MDA-MB-
231 MCF-7 
C26 P388 
Vindoline > 100
b
 > 100 > 100 > 100 > 100 
Br-Vindoline > 100 > 100 > 100 > 100 > 100 
Br-Vind-(L)-Trp-OMe (1a) 56.8 (9.8)
b
 n.d. n.d. 18.4 (2.1) 5.3 (1.5) 
Br-Vind-(D)-Trp-OMe (1b) 73.8 (10.4)
b
 37.3 (13.7) 28.5 (5.7) 21.6 (4.3) 15.9 (2.8) 
Br-Vind-Arg8 11.6 (5.3) 10.3 (3.3) 12.0 (3.3) 25.9 (2.7) 26.6 (5.0) 
Br-Vind-(L)-Trp-Arg8 11.5 (4.6) 13.2 (0.4) 6.4 (3.6) 4.3 (0.41) 3.1 (0.5) 
Br-Vind-(D)-Trp-Arg8 15.1 (0.5) 10.0 (3.7) 5.1 (1.1) 10.8 (0.7) 18.0 (1.2) 
a
 The cells were incubated with compound for 3 h, after cultured in serum-containing medium for 3 days. 
The IC50 values were determined by MTT assay as described in the text. Standard deviation values (sd) are 
also presented. 
b
 From the literature (10) 
n.d. not determined 
 
